文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

早期脓毒症管理集束化治疗与医院获得性或社区获得性脓毒症患者死亡率的关联

Association of a Care Bundle for Early Sepsis Management With Mortality Among Patients With Hospital-Onset or Community-Onset Sepsis.
PubMed 文献 · JAMA Intern Med · 2020-01-01
一句话结论回顾性队列显示,SEP-1集束化治疗依从性与死亡率改善无关;社区获得性脓毒症中乳酸检测与死亡率降低相关,医院获得性脓毒症中仅广谱静脉抗生素与死亡率降低相关。

该回顾性队列研究纳入加州大学4所医院2014年10月1日至2017年10月1日收治的6404例符合Sepsis-3标准的成人脓毒症患者,其中医院获得性脓毒症2296例(35.9%),社区获得性脓毒症4108例(64.1%)。在社区获得性脓毒症中,3小时内乳酸检测与死亡率降低相关(绝对差-7.61%,95%CI -14.70%至-0.54%),血培养和广谱静脉抗生素与血管升压药使用天数减少相关。在医院获得性脓毒症中,仅广谱静脉抗生素与死亡率降低相关(绝对差-5.20%,95%CI -9.84%至-0.56%)。完全依从SEP-1集束化治疗与两个队列死亡率降低均无显著关联,且与社区获得性脓毒症血管升压药天数增加相关(绝对差0.31天,95%CI 0.11-0.51天)。作者认为当前脓毒症质量指标可能需要改进。

要点

  • 社区获得性脓毒症中,3小时内乳酸检测与死亡率降低相关(绝对差-7.61%,95%CI -14.70%至-0.54%)。
  • 医院获得性脓毒症中,仅广谱静脉抗生素与死亡率降低相关(绝对差-5.20%,95%CI -9.84%至-0.56%)。
  • 完全依从SEP-1集束化治疗与两个队列死亡率降低均无显著关联(社区获得性绝对差-0.07%,95%CI -3.02%至2.88%;医院获得性绝对差-0.42%,95%CI -6.77%至5.93%)。
  • 社区获得性脓毒症中,完全依从SEP-1与血管升压药天数增加相关(绝对差0.31天,95%CI 0.11-0.51天)。
  • 社区获得性脓毒症中,血培养与血管升压药天数减少相关(绝对差-1.10天,95%CI -1.85至-0.34天),广谱静脉抗生素与血管升压药天数减少相关(绝对差-0.62天,95%CI -1.02至-0.22天)。

适用人群与场景

  • 成人住院患者,诊断为脓毒症或播散性感染,且实验室或生命体征符合Sepsis-3标准。
  • 根据脓毒症时间零点发生在到达急诊科后还是住院区域,分为社区获得性脓毒症和医院获得性脓毒症队列。

诊断标准与关键阈值

  • 脓毒症诊断依据Sepsis-3(第三次国际共识定义脓毒症和脓毒性休克)标准。
  • 时间零点定义为脓毒症发生时间,用于区分社区获得性和医院获得性脓毒症。

研究设计与关键结果

  • 研究类型:回顾性队列研究,纳入4所加州大学医院2014年10月1日至2017年10月1日的数据,共6404例患者 encounters(3535例男性[55.2%],平均[SD]年龄64.0[18.2]岁),其中医院获得性脓毒症2296例(35.9%),社区获得性脓毒症4108例(64.1%)。
  • 社区获得性脓毒症:3小时内乳酸检测与死亡率降低相关(绝对差-7.61%,95%CI -14.70%至-0.54%);血培养与血管升压药天数减少相关(绝对差-1.10天,95%CI -1.85至-0.34天);广谱静脉抗生素与血管升压药天数减少相关(绝对差-0.62天,95%CI -1.02至-0.22天)。
  • 医院获得性脓毒症:广谱静脉抗生素是唯一与任何结局改善显著相关的集束化组分(死亡率绝对差-5.20%,95%CI -9.84%至-0.56%)。
  • 完全依从SEP-1集束化治疗:社区获得性脓毒症中与血管升压药天数增加相关(绝对差0.31天,95%CI 0.11-0.51天),与死亡率降低无显著关联(绝对差-0.07%,95%CI -3.02%至2.88%);医院获得性脓毒症中与死亡率降低无显著关联(绝对差-0.42%,95%CI -6.77%至5.93%)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为当前脓毒症质量指标可能需要改进。
  • 在急诊科就诊的社区获得性脓毒症患者中,SEP-1的多个组分与死亡率降低或血管升压药治疗天数减少相关。
  • 当时间零点发生在住院单元时,仅广谱静脉抗生素治疗与死亡率降低相关。
  • 完全依从SEP-1集束化治疗与两个队列的死亡率改善均无显著关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The Early Management Bundle for Severe Sepsis/Septic Shock (SEP-1) is a quality metric based on a care bundle for early sepsis management. Published evidence on the association of SEP-1 with mortality is mixed and largely excludes cases of hospital-onset sepsis.

OBJECTIVE: To assess the association of the SEP-1 bundle with mortality and organ dysfunction in cohorts with hospital-onset or community-onset sepsis.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from 4 University of California hospitals from October 1, 2014, to October 1, 2017. Adult inpatients with a diagnosis consistent with sepsis or disseminated infection and laboratory or vital signs meeting the Sepsis-3 (Third International Consensus Definitions for Sepsis and Septic Shock) criteria were divided into community-onset sepsis and hospital-onset sepsis cohorts based on whether time 0 of sepsis occurred after arrival in the emergency department or an inpatient area. Data were analyzed from April to October 2019. Additional analyses were performed from December 2019 to January 2020.

EXPOSURES: Administration of SEP-1 and 4 individual bundle components (serum lactate level testing, blood culture, broad-spectrum intravenous antibiotic treatment, and intravenous fluid treatment).

MAIN OUTCOMES AND MEASURES: The primary outcome was in-hospital mortality. The secondary outcome was days requiring vasopressor support, measured as vasopressor days.

RESULTS: Among the 6404 patient encounters identified (3535 men [55.2%]; mean [SD] age, 64.0 [18.2] years), 2296 patients (35.9%) had hospital-onset sepsis. Among 4108 patients (64.1%) with community-onset sepsis, serum lactate level testing within 3 hours of time 0 was associated with reduced mortality (absolute difference, -7.61%; 95% CI, -14.70% to -0.54%). Blood culture (absolute difference, -1.10 days; 95% CI, -1.85 to -0.34 days) and broad-spectrum intravenous antibiotic treatment (absolute difference, -0.62 days; 95% CI, -1.02 to -0.22 days) were associated with fewer vasopressor days. Among patients with hospital-onset sepsis, broad-spectrum intravenous antibiotic treatment was the only bundle component significantly associated with any improved outcome (mortality difference, -5.20%; 95% CI, -9.84% to -0.56%). Care that was adherent to the complete SEP-1 bundle was associated with increased vasopressor days in patients with community-onset sepsis (absolute difference, 0.31 days; 95% CI, 0.11-0.51 days) but was not significantly associated with reduced mortality in either cohort (absolute difference, -0.07%; 95% CI, -3.02% to 2.88% in community-onset; absolute difference, -0.42%; 95% CI, -6.77% to 5.93% in hospital-onset).

CONCLUSIONS AND RELEVANCE: SEP-1-adherent care was not associated with improved outcomes of sepsis. Although multiple components of SEP-1 were associated with reduced mortality or decreased days of vasopressor therapy for patients who presented with sepsis in the emergency department, only broad-spectrum intravenous antibiotic treatment was associated with reduced mortality when time 0 occurred in an inpatient unit. Current sepsis quality metrics may need refinement.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Baghdadi JD, Brook RH, Uslan DZ, et al. Association of a Care Bundle for Early Sepsis Management With Mortality Among Patients With Hospital-Onset or Community-Onset Sepsis. JAMA Intern Med. 2020. PMID: 32250412. doi:10.1001/jamainternmed.2020.0183

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。